Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12457288 | 0.90 | LMNA (0.54) | LMNARAB9ANPC1L3MBTL1TSHR | |
| SCHEMBL23867673 | 0.90 | LMNA (0.54) | LMNARAB9ANPC1L3MBTL1TSHR | |
| SCHEMBL11938505 | 0.87 | LMNA (0.54) | LMNARAB9ANPC1L3MBTL1TSHR | |
| SCHEMBL12757837 | 0.87 | LMNA (0.54) | LMNARAB9ANPC1L3MBTL1TSHR | |
| SCHEMBL8548256 | 0.85 | RAB9A (0.57) | LMNARAB9ANPC1L3MBTL1TSHR | |
| SCHEMBL1627176 | 0.84 | RAB9A (0.54) | LMNARAB9ANPC1L3MBTL1TSHR | |
| SCHEMBL8548739 | 0.82 | RAB9A (0.69) | LMNARAB9ANPC1L3MBTL1TSHR | |
| SCHEMBL14583007 | 0.81 | LMNA (0.51) | LMNARAB9ANPC1L3MBTL1TSHR | |
| SCHEMBL8546894 | 0.81 | LMNA (0.64) | LMNARAB9ANPC1L3MBTL1TSHR | |
| SCHEMBL8542920 | 0.80 | RAB9A (0.57) | LMNARAB9ANPC1L3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7824659-B2 | Methods of making radiolabeled tracers and precursors thereof | LANTHEUS MEDICAL IMAGING, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| EP-1926500-A2 | METHODS OF MAKING RADIOLABELED TRACERS AND PRECURSORS THEREOF | Bristol-Myers Squibb Pharma Company (US) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007021858-A2 | METHODS OF MAKING RADIOLABELED TRACERS AND PRECURSORS THEREOF | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20070036716-A1 | 2-tert-Butyl-4-chloro-5-[4-(2-[18F]-fluoro-ethoxymethyl)-benzyloxy]-2H-pyridazin-3-one used as Positron Emission Tomography (PET) radiolabeled tracers | LANTHEUS MEDICAL IMAGING, INC. | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070036716-A1 | 2-tert-Butyl-4-chloro-5-[4-(2-[18F]-fluoro-ethoxymethyl)-benzyloxy]-2H-pyridazin-3-one used as Positron Emission Tomography (PET) radiolabeled tracers | TMEM14C, TERT, TK1 | LMNA 3579/4885RAB9A 808/4885NPC1 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.